The Single Most Important Catalyst for Valeant Pharma (VRX) Near-Term...
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Valeant (VRX) PT Cut to $40 at Canaccord Genuity
March 16, 2016 9:40 AM EDTCanaccord Genuity analyst Neil Maruok reiterated a Hold rating and lowered his price target on Valeant Pharmaceuticals (NYSE: VRX) to $40.00 (from $75.00).
Maruok commented, "guidance was even lower than our base-case scenario and we believe has begun to erode investor confidence in Valeants underlying business. We believe that the implementation of the partnership with Walgreens,... More
UPDATE: Piper Jaffray Downgrades Valeant Pharmaceuticals (VRX) to Underweight
March 15, 2016 11:15 AM EDT(Updated - March 15, 2016 11:20 AM EDT)
Piper Jaffray downgraded Valeant Pharmaceuticals (NYSE: VRX) from Neutral to Underweight. Analyst David Amsellem called Valeant a "broken company" and noted trouble spots across a number of segments.
Amsellem explained the downgrade, "VRX reported 4Q15 adjusted... More
Valeant Pharma (VRX) Results Suggest Disruption in the Business - Evecore ISI's Raffat
March 15, 2016 10:56 AM EDTEvercore ISI analyst, Umer Raffat, commented on Valeant Pharma (NYSE: VRX) after the call.
"I think it will be an understatement to say that this has clearly been a very humbling call for me," he said.
".. today's results suggests that while... More
Valeant Pharma (VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg
March 15, 2016 9:48 AM EDTValeant Pharma (NYSE: VRX) CEO said his best estimate is 10-K will be filed in April - Bloomberg
... MoreValeant Pharma (VRX) Misses Dramatically Reduced Expectations - BMO
March 15, 2016 9:00 AM EDTBMO Capital analyst, Alex Arfaei, posted an earnings flash on Valeant Pharmaceuticals' (NYSE: VRX) miss and guide down. The call is ongoing and began at 8:00AM.
This morning, Valeant reported unaudited 4Q15 revenues of $2.78B, 1% above consensus of $2.75B. Gross margin of 75.6%... More
Valeant Pharma (VRX) Won't File 10-K Within 15-Day Extension Period
March 15, 2016 6:19 AM EDTValeant Pharma (NYSE: VRX) disclosed the following on Tuesday:
Item 2.02 Results of Operations and Financial Condition
On March 15, 2016, Valeant Pharmaceuticals International, Inc. (the Company) issued a press release announcing preliminary unaudited financial results for the fourth quarter ended December 31, 2015. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
The fourth quarter 2015 results are preliminary because, as previously announced, the Company has delayed the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 pending completion of the Companys... More
Valeant Pharma (VRX) Misses Q4 EPS by 11c; Cuts Q1, FY16 Outlook
March 15, 2016 6:03 AM EDTValeant Pharma (NYSE: VRX) reported Q4 EPS of $2.50, $0.11 worse than the analyst estimate of $2.61. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.
GUIDANCE:
Valeant Pharma sees Q1 2016 EPS of $1.30 - $1.55, versus prior guidance of $2.35 - $2.55 and the consensus of $2.63. Valeant Pharma sees Q1 2016 revenue of $2.3 - $2.4 billion, versus prior guidance of $2.8 - $3.1 billion and the consensus of $2.82 billion.
Valeant Pharma sees FY2016 EPS... More
